Kw-6356 (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 6 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04342273 (ClinicalTrials.gov) | March 31, 2020 | 8/4/2020 | A Through QT/QTc Study of KW-6356 | A Through QT/QTc Study of KW-6356 in Japanese Healthy Adults | Parkinson's Disease | Drug: KW-6356;Drug: Placebo;Drug: Moxifloxacin | Kyowa Kirin Co., Ltd. | NULL | Completed | 20 Years | 54 Years | All | 128 | Phase 1 | Japan |
2 | NCT04070495 (ClinicalTrials.gov) | August 27, 2019 | 26/8/2019 | A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin | A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin (A Drug Interaction Study With a CYP3A4/5 Inhibitor or Inducer) | Parkinson's Disease | Drug: KW-6356;Drug: Clarithromycin;Drug: Rifampicin | Kyowa Kirin Co., Ltd. | NULL | Completed | 20 Years | 44 Years | Male | 20 | Phase 1 | Japan |
3 | NCT03970798 (ClinicalTrials.gov) | May 22, 2019 | 23/5/2019 | A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin | A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin | Parkinson's Disease | Drug: Midazolam;Drug: Caffeine;Drug: Rosuvastatin;Drug: KW-6356 | Kyowa Kirin Co., Ltd. | NULL | Completed | 20 Years | 44 Years | Male | 50 | Phase 1 | Japan |
4 | NCT03830528 (ClinicalTrials.gov) | February 26, 2019 | 3/2/2019 | A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects | A Phase I Study of KW-6356 in Japanese and Caucasian Healthy Adults | Parkinson's Disease | Drug: KW-6356 Low Dose;Drug: KW-6356 Middle Dose;Drug: KW-6356 High Dose;Drug: KW-6356 X Dose;Drug: KW-6356 Y Dose;Drug: Placebo | Kyowa Kirin Co., Ltd. | NULL | Completed | 20 Years | 44 Years | Male | 48 | Phase 1 | Japan |
5 | NCT03703570 (ClinicalTrials.gov) | September 29, 2018 | 5/10/2018 | A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations | A Phase 2b Study of KW-6356 in Subjects With Parkinson's Disease on Treatment With Levodopa-containing Preparations | Parkinson's Disease | Drug: KW-6356;Drug: Placebo | Kyowa Kirin Co., Ltd. | NULL | Completed | 20 Years | 80 Years | All | 502 | Phase 2 | Japan |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT02939391 (ClinicalTrials.gov) | September 2016 | 17/10/2016 | A Study of KW-6356 in Subjects With Early Parkinson's Disease | An Early Phase 2 Study of KW-6356 in Subject With Early Parkinson's Disease | Parkinson's Disease | Drug: KW-6356;Drug: Placebo | Kyowa Kirin Co., Ltd. | NULL | Completed | 20 Years | 80 Years | All | 175 | Phase 2 | Japan |